D. Mudawi, N. Kassem, Abdulqadir Nashwan, M. Yassin
{"title":"尼洛替尼的皮肤表现","authors":"D. Mudawi, N. Kassem, Abdulqadir Nashwan, M. Yassin","doi":"10.15226/ijhbd/3/1/00120","DOIUrl":null,"url":null,"abstract":"Nilotinib is a highly selective second-generation Bcr-Abl tyrosine kinaseInhibitor (TKIs), which is effective in patients with Philadelphia chromosome–positive chronic myeloid leukemia (CML). Tyrosine kinase inhibitors have broadly similar types of non-hematological adverse side effects (AES), but some of the AES are specific to one drug compared to the others. In general, the TKIs are well tolerated with mostly (grade1-2) toxicities, and relatively limited grade (34) toxicities. For best management of CML patients receiving TKI therapy, early recognition and knowledge of potential toxicities are required, allowing for optimal management of the condition without interruption of the drug.","PeriodicalId":225199,"journal":{"name":"International Journal of Hematology and Blood Disorders","volume":"38 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Cutaneous manifestations of Nilotinib\",\"authors\":\"D. Mudawi, N. Kassem, Abdulqadir Nashwan, M. Yassin\",\"doi\":\"10.15226/ijhbd/3/1/00120\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Nilotinib is a highly selective second-generation Bcr-Abl tyrosine kinaseInhibitor (TKIs), which is effective in patients with Philadelphia chromosome–positive chronic myeloid leukemia (CML). Tyrosine kinase inhibitors have broadly similar types of non-hematological adverse side effects (AES), but some of the AES are specific to one drug compared to the others. In general, the TKIs are well tolerated with mostly (grade1-2) toxicities, and relatively limited grade (34) toxicities. For best management of CML patients receiving TKI therapy, early recognition and knowledge of potential toxicities are required, allowing for optimal management of the condition without interruption of the drug.\",\"PeriodicalId\":225199,\"journal\":{\"name\":\"International Journal of Hematology and Blood Disorders\",\"volume\":\"38 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-08-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Hematology and Blood Disorders\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15226/ijhbd/3/1/00120\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Hematology and Blood Disorders","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15226/ijhbd/3/1/00120","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Nilotinib is a highly selective second-generation Bcr-Abl tyrosine kinaseInhibitor (TKIs), which is effective in patients with Philadelphia chromosome–positive chronic myeloid leukemia (CML). Tyrosine kinase inhibitors have broadly similar types of non-hematological adverse side effects (AES), but some of the AES are specific to one drug compared to the others. In general, the TKIs are well tolerated with mostly (grade1-2) toxicities, and relatively limited grade (34) toxicities. For best management of CML patients receiving TKI therapy, early recognition and knowledge of potential toxicities are required, allowing for optimal management of the condition without interruption of the drug.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
